CO2019014677A2 - Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos - Google Patents

Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos

Info

Publication number
CO2019014677A2
CO2019014677A2 CONC2019/0014677A CO2019014677A CO2019014677A2 CO 2019014677 A2 CO2019014677 A2 CO 2019014677A2 CO 2019014677 A CO2019014677 A CO 2019014677A CO 2019014677 A2 CO2019014677 A2 CO 2019014677A2
Authority
CO
Colombia
Prior art keywords
hiv
poxvirus vectors
antigens
methods
same
Prior art date
Application number
CONC2019/0014677A
Other languages
English (en)
Inventor
Frank Wegmann
Johannes Petrus Maria Langedijk
Jerome Hubertina Henricus Victor Custers
Viki Bockstal
Markus Kalla
Original Assignee
Janssen Vaccines & Prevention Bv
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv, Bavarian Nordic As filed Critical Janssen Vaccines & Prevention Bv
Publication of CO2019014677A2 publication Critical patent/CO2019014677A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan vectores de poxvirus que codifican un antígeno de envoltura de VIH sintético y otros antígenos de VIH, así como composiciones que contienen tales vectores de poxvirus y usos de tales vectores de poxvirus como vacunas para proporcionar inmunidad mejorada contra el 5 VIH; también se proporcionan combinaciones de vacunas que contienen los vectores de poxvirus descritos, vectores de adenovirus que codifican uno o más antígenos de VIH, y uno o más polipéptidos antigénicos de VIH aislados, y métodos para usar las combinaciones de vacunas para proporcionar inmunidad mejorada contra el VIH.
CONC2019/0014677A 2017-06-15 2019-12-24 Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos CO2019014677A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520079P 2017-06-15 2017-06-15
PCT/IB2018/054386 WO2018229711A1 (en) 2017-06-15 2018-06-14 Poxvirus vectors encoding hiv antigens, and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2019014677A2 true CO2019014677A2 (es) 2020-01-17

Family

ID=63103974

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0014677A CO2019014677A2 (es) 2017-06-15 2019-12-24 Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos

Country Status (12)

Country Link
US (2) US11229693B2 (es)
EP (1) EP3638302B1 (es)
JP (1) JP7272965B2 (es)
KR (1) KR20200015759A (es)
CN (1) CN110958887B (es)
AU (1) AU2018283811B2 (es)
BR (1) BR112019026126A2 (es)
CA (1) CA3066573A1 (es)
CO (1) CO2019014677A2 (es)
EA (1) EA202090049A1 (es)
MA (1) MA49397A (es)
WO (1) WO2018229711A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11730823B2 (en) 2016-10-03 2023-08-22 President And Fellows Of Harvard College Delivery of therapeutic RNAs via ARRDC1-mediated microvesicles
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
WO2020237052A1 (en) 2019-05-22 2020-11-26 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR102636452B1 (ko) 2020-03-04 2024-02-14 주식회사 바이오앱 식물체에서 ｃｏｖｉｄ－１９ 백신용 단백질을 발현하는 재조합 벡터 및 이를 이용한 백신 조성물의 제조방법
KR102657261B1 (ko) 2020-04-03 2024-04-15 조선대학교산학협력단 Ｃｏｖｉｄ－１９ 진단을 위한 재조합 코로나－１９ 바이러스 스파이크 단백질의 생산 및 이의 용도
JP2023546156A (ja) * 2020-10-16 2023-11-01 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｈｉｖを標的にするｗｗドメイン活性化細胞外ベシクル
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US5761893A (en) 1996-10-22 1998-06-09 Lofquist Welding, Inc. Crop saving attachment for the snouts of combines
ES2354578T3 (es) 1999-05-17 2011-03-16 Crucell Holland B.V. Adenovirus recombinante humano de serotipo ad26.
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2384271A1 (en) 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
DE60116371T3 (de) 2000-11-23 2016-11-17 Bavarian Nordic A/S Variante des modifizierten vaccinia ankara virus
CA2452119C (en) 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
AU2002356690B2 (en) 2001-12-04 2008-07-24 Bavarian Nordic A/S Flavivirus NS1 subunit vaccine
NZ533302A (en) 2001-12-10 2005-11-25 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions containing a disaaccharide and a pharmaceutically acceptable polymer i.e. dextran or polyvinylpyrrolidon (PVP)
IL164802A0 (en) 2002-04-25 2005-12-18 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
PL216760B1 (pl) 2002-05-16 2014-05-30 Bavarian Nordic As Rekombinowany modyfikowany wirus krowianki Ankara oraz sposób jego otrzymywania i zastosowania
WO2004044155A2 (en) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
EP1578766B1 (en) 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
EP1585542B1 (en) 2002-12-27 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
EP2359851A3 (en) 2003-03-28 2011-08-31 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services MVA expressing modified hiv envelope, gag, and pol genes
US20070166784A1 (en) 2003-09-15 2007-07-19 Barnett Susan W Combination approaches for generating immune responses
WO2005052119A2 (en) 2003-11-19 2005-06-09 Beth Israel Deaconess Medical Center Adjuvants of immune response
PL2163260T3 (pl) 2004-01-23 2017-12-29 Msd Italia S.R.L. Szympansie adenowirusowe nośniki szczepionek
US20080274134A1 (en) 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
CA2573702C (en) 2004-07-16 2013-10-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Vaccine constructs and combination of vaccines designed to improve the breadth of the immune response to diverse strains and clades of hiv
JP5178196B2 (ja) 2004-08-27 2013-04-10 アメリカ合衆国 クレードＡ／Ｇ、クレードＢ、およびクレードＣ改変ＨＩＶｅｎｖ、ｇａｇ、およびｐｏｌ遺伝子を発現する組換えＭＶＡウイルス
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
CA2656741A1 (en) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP2040747A4 (en) 2006-06-19 2010-08-25 Progenics Pharm Inc SOLUBLE STABILIZED TRIMERIC HIV ENV PROTEINS AND USES THEREOF
WO2008063331A2 (en) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US20080279879A1 (en) 2006-11-17 2008-11-13 New York University INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
SI3335728T1 (sl) 2008-10-10 2020-04-30 Children's Medical Center Corporation Biokemično stabilizirano HIV-1 ENV trimer cepivo
PL2358757T3 (pl) 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
JP2012509678A (ja) 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ 組換えウイルス発現のためのプロモーター
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CA3108979A1 (en) 2009-02-02 2010-08-05 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2011082087A2 (en) 2010-01-04 2011-07-07 Kj Biosciences, Llc Dps fusion proteins for use in vaccines and diagnostics
EP2529010B1 (en) 2010-01-28 2017-04-19 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
EA023816B1 (ru) 2010-02-15 2016-07-29 Круселл Холланд Б.В. СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
EP2611465A4 (en) 2010-08-31 2014-06-04 Theraclone Sciences Inc NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
WO2012082918A1 (en) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Adenovirus serotype 26 and serotype 35 filovirus vaccines
WO2013036791A2 (en) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Modified adenoviral vectors and methods of treatment using same
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
WO2013055908A1 (en) 2011-10-12 2013-04-18 The Scripps Research Institute An hiv-1 gp120 mini v3 loop and uses thereof
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014047261A1 (en) 2012-09-19 2014-03-27 Beth Israel Deaconess Medical Center, Inc. Viruses associated with immunodeficiency and enteropathy and methods using same
EP3778904A1 (en) 2012-10-28 2021-02-17 Bavarian Nordic A/S Pr13.5 promoter for robust t-cell and antibody responses
EP2920313B1 (en) 2012-11-16 2019-06-12 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
MY187152A (en) 2013-01-07 2021-09-06 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
WO2014124301A1 (en) 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
WO2015048770A2 (en) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Antibody therapies for human immunodeficiency virus (hiv)
AU2015222153A1 (en) 2014-02-28 2016-09-01 Beth Israel Deaconess Medical Center Inc. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
CN103992396B (zh) 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
EP3189067B1 (en) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
EP3197489B1 (en) * 2014-09-26 2021-02-17 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
SI3271729T1 (sl) 2015-03-18 2021-04-30 Janssen Vaccines & Prevention B.V. Testi za rekombinantne ekspresijske sisteme
CA2984991A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
SI3584252T1 (sl) 2015-12-15 2021-11-30 Janssen Vaccines & Prevention B.V. Antigeni, vektorji, sestavki virusa človeške imunske pomanjkljivosti in postopki njihove uporabe
CA3027454A1 (en) 2016-06-16 2017-12-21 Janssen Vaccines & Prevention B.V. Hiv vaccine formulation
JP2019526580A (ja) 2016-09-02 2019-09-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 抗レトロウイルス処置を受けている対象においてヒト免疫不全ウイルス感染に対する免疫応答を誘発するための方法
US10793607B2 (en) 2016-09-15 2020-10-06 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
CA3077630A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof

Also Published As

Publication number Publication date
AU2018283811B2 (en) 2022-10-20
BR112019026126A2 (pt) 2020-06-30
WO2018229711A1 (en) 2018-12-20
CN110958887A (zh) 2020-04-03
US11229693B2 (en) 2022-01-25
US11723970B2 (en) 2023-08-15
EP3638302B1 (en) 2024-03-13
US20200138938A1 (en) 2020-05-07
CA3066573A1 (en) 2018-12-20
CN110958887B (zh) 2023-10-31
AU2018283811A1 (en) 2020-01-02
JP7272965B2 (ja) 2023-05-12
EP3638302A1 (en) 2020-04-22
EA202090049A1 (ru) 2020-04-15
US20220088172A1 (en) 2022-03-24
EP3638302C0 (en) 2024-03-13
KR20200015759A (ko) 2020-02-12
MA49397A (fr) 2020-04-22
JP2020527029A (ja) 2020-09-03

Similar Documents

Publication Publication Date Title
CO2019014677A2 (es) Vectores de poxvirus que codifican antígenos del virus de inmunodeficiencia humana (vih), y métodos de uso de los mismos
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CL2023003001A1 (es) Novedosas proteínas de la cápside del virus adenoasociado
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
DOP2024000040A (es) Vacunas para vhb y métodos de tratamiento de vhb
MY175620A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
AR110632A1 (es) Vectores del adenovirus canino
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
DOP2023000137A (es) Vacunas contra el vih y métodos de uso
AR115069A1 (es) Virus vacuna quimérico sintético
ECSP18081582A (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
CL2019000705A1 (es) Nuevos promotores.
UY36995A (es) Proteínas de fusión de e2 y fmdv y sus usos
BR112016017242A2 (pt) Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1
BR112018072592A2 (pt) vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
CO2021012294A2 (es) Composiciones de lawsonia intracellularis y métodos de uso de las mismas
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
UY36860A (es) Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos